M3315

MJ33 lithium salt

powder, ≥90% (NMR)

• Synonim(y): 1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol lithium
• Wzór empiryczny (zapis Hilla): C₂₂H₄₃F₃O₆PLi
• Numer CAS: 199106-13-3
• Masa cząsteczkowa: 498.48
• Numer MDL: MFCD03787978
• Kod UNSPSC: 41106300
• Identyfikator substancji w PubChem: 24278549
• NACRES: NA.77

Właściwości

• Poziom jakości: 100
• Próba: ≥90% (NMR)
• Formularz: powder
• kolor: white to beige
• rozpuszczalność: H₂O: ≥5 mg/mL (warmed at 60 °C)
• temp. przechowywania: 2-8°C
• ciąg SMILES: CCCCCCCCCCCCCCCCOCC(COCC(F)(F)F)OP(OC)([O-])=O.[Li+]
• InChI: 1S/C22H44F3O6P.Li/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-29-18-21(31-32(26,27)28-2)19-30-20-22(23,24)25;/h21H,3-20H2,1-2H3,(H,26,27);/q;+1/p-1
• Klucz InChI: GDLMLQJISATCEL-UHFFFAOYSA-M

Opis

Zastosowanie

MJ33 lithium salt has been used as a peroxiredoxin VI (Prdx6) inhibitor:

• to study its specific Prdx6 peroxidase activity in vitro and in breast cancer cell line (MCF-7) cell lysates[1]
• to study its effects on a mouse model of acute lung injury associated with exposure to hyperoxia[2]
• to study its potential use as a therapeutic agent[3]

Działania biochem./fizjol.

MJ33 acts as a non-toxic and potent inhibitor of agonist-induced activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase type 2 (NOX2). It also prevents lung injuries associated with lung inflammation in mice. MJ33 is a fluorinated lipid analog, which blocks the enzyme by mimicking the transition state of the substrate.[2]

Novel, active site directed, specific, competitive and reversible inhibitor of phospholipase A₂ (PLA₂).

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable
• Środki ochrony indywidualnej: Eyeshields, Gloves, type N95 (US)